Bio-Techne Corporation Logo

Bio-Techne Corporation

TECH

(2.5)
Stock Price

71,49 USD

20.44% ROA

11.47% ROE

47.28x PER

Market Cap.

11.664.353.250,00 USD

27.51% DER

0.43% Yield

19.58% NPM

Bio-Techne Corporation Stock Analysis

Bio-Techne Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bio-Techne Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

2 DER

The stock has a minimal amount of debt (28%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

4 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

5 ROE

ROE in an average range (12.85%) suggests satisfactory profitability and decent utilization of shareholders' equity.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (302), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (4.83x) suggests it's overvalued, potentially making it an expensive investment.

8 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

10 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

11 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

Bio-Techne Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bio-Techne Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Bio-Techne Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bio-Techne Corporation Revenue
Year Revenue Growth
1989 12.500.000
1990 15.700.000 20.38%
1991 19.300.000 18.65%
1992 22.300.000 13.45%
1993 28.700.000 22.3%
1994 40.300.000 28.78%
1995 47.700.000 15.51%
1996 54.600.000 12.64%
1997 60.900.000 10.34%
1998 67.300.000 9.51%
1999 90.900.000 25.96%
2000 103.838.155 12.46%
2001 115.356.562 9.99%
2002 130.900.395 11.87%
2003 145.010.900 9.73%
2004 161.257.000 10.07%
2005 178.652.000 9.74%
2006 202.617.000 11.83%
2007 223.482.000 9.34%
2008 257.420.000 13.18%
2009 263.956.000 2.48%
2010 269.047.000 1.89%
2011 289.962.000 7.21%
2012 314.560.000 7.82%
2013 310.575.000 -1.28%
2014 357.763.000 13.19%
2015 452.246.000 20.89%
2016 499.023.000 9.37%
2017 563.003.000 11.36%
2018 642.993.000 12.44%
2019 714.006.000 9.95%
2020 738.691.000 3.34%
2021 931.032.000 20.66%
2022 1.105.599.000 15.79%
2023 1.136.702.000 2.74%
2024 1.107.740.000 -2.61%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bio-Techne Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 6.500.000 100%
1995 8.600.000 24.42%
1996 10.400.000 17.31%
1997 11.700.000 11.11%
1998 10.600.000 -10.38%
1999 12.000.000 11.67%
2000 11.198.309 -7.16%
2001 14.522.233 22.89%
2002 17.470.267 16.87%
2003 20.581.343 15.12%
2004 20.773.000 0.92%
2005 18.379.000 -13.03%
2006 18.825.000 2.37%
2007 20.082.000 6.26%
2008 22.394.000 10.32%
2009 23.564.000 4.97%
2010 25.121.000 6.2%
2011 25.985.000 3.32%
2012 27.912.000 6.9%
2013 29.257.000 4.6%
2014 30.945.000 5.45%
2015 40.853.000 24.25%
2016 45.187.000 9.59%
2017 53.514.000 15.56%
2018 55.329.000 3.28%
2019 62.413.000 11.35%
2020 65.192.000 4.26%
2021 70.603.000 7.66%
2022 87.140.000 18.98%
2023 92.493.000 5.79%
2024 95.992.000 3.65%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bio-Techne Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 11.200.000 100%
1996 13.000.000 13.85%
1997 14.600.000 10.96%
1998 15.400.000 5.19%
1999 16.900.000 8.88%
2000 17.315.131 2.4%
2001 17.714.215 2.25%
2002 19.554.195 9.41%
2003 19.376.538 -0.92%
2004 21.725.000 10.81%
2005 24.476.000 11.24%
2006 27.604.000 11.33%
2007 30.965.000 10.85%
2008 36.715.000 15.66%
2009 33.164.000 -10.71%
2010 32.175.000 -3.07%
2011 35.897.000 10.37%
2012 41.683.000 13.88%
2013 43.384.000 3.92%
2014 60.716.000 28.55%
2015 119.401.000 49.15%
2016 140.879.000 15.25%
2017 153.326.000 8.12%
2018 240.636.000 36.28%
2019 236.867.000 -1.59%
2020 240.882.000 1.67%
2021 289.924.000 16.92%
2022 339.001.000 14.48%
2023 352.438.000 3.81%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bio-Techne Corporation EBITDA
Year EBITDA Growth
1989 700.000
1990 1.700.000 58.82%
1991 2.600.000 34.62%
1992 5.800.000 55.17%
1993 8.600.000 32.56%
1994 9.800.000 12.24%
1995 10.900.000 10.09%
1996 13.700.000 20.44%
1997 16.900.000 18.93%
1998 22.300.000 24.22%
1999 36.100.000 38.23%
2000 51.996.165 30.57%
2001 58.543.402 11.18%
2002 83.006.756 29.47%
2003 74.192.312 -11.88%
2004 90.618.000 18.13%
2005 105.034.000 13.73%
2006 116.542.000 9.87%
2007 133.722.000 12.85%
2008 154.190.000 13.27%
2009 166.180.000 7.22%
2010 161.545.000 -2.87%
2011 173.581.000 6.93%
2012 181.165.000 4.19%
2013 168.259.000 -7.67%
2014 159.750.000 -5.33%
2015 147.023.000 -8.66%
2016 150.593.000 2.37%
2017 121.784.000 -23.66%
2018 136.178.000 10.57%
2019 146.719.000 7.18%
2020 157.419.000 6.8%
2021 237.296.000 33.66%
2022 397.659.000 40.33%
2023 406.182.000 2.1%
2024 337.608.000 -20.31%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bio-Techne Corporation Gross Profit
Year Gross Profit Growth
1989 6.400.000
1990 8.400.000 23.81%
1991 10.400.000 19.23%
1992 12.700.000 18.11%
1993 16.900.000 24.85%
1994 25.100.000 32.67%
1995 30.900.000 18.77%
1996 37.500.000 17.6%
1997 43.900.000 14.58%
1998 49.500.000 11.31%
1999 65.900.000 24.89%
2000 80.509.605 18.15%
2001 86.931.656 7.39%
2002 98.392.549 11.65%
2003 109.614.726 10.24%
2004 126.370.000 13.26%
2005 141.839.000 10.91%
2006 156.899.000 9.6%
2007 176.815.000 11.26%
2008 204.531.000 13.55%
2009 208.468.000 1.89%
2010 214.584.000 2.85%
2011 224.937.000 4.6%
2012 235.804.000 4.61%
2013 231.110.000 -2.03%
2014 251.411.000 8.07%
2015 307.277.000 18.18%
2016 336.659.000 8.73%
2017 374.541.000 10.11%
2018 432.143.000 13.33%
2019 473.491.000 8.73%
2020 483.194.000 2.01%
2021 632.850.000 23.65%
2022 756.496.000 16.34%
2023 769.815.000 1.73%
2024 740.764.000 -3.92%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bio-Techne Corporation Net Profit
Year Net Profit Growth
1989 400.000
1990 1.000.000 60%
1991 1.600.000 37.5%
1992 2.000.000 20%
1993 4.400.000 54.55%
1994 5.100.000 13.73%
1995 6.700.000 23.88%
1996 8.600.000 22.09%
1997 10.900.000 21.1%
1998 15.200.000 28.29%
1999 16.700.000 8.98%
2000 26.582.797 37.18%
2001 34.045.376 21.92%
2002 27.129.669 -25.49%
2003 45.396.293 40.24%
2004 52.928.000 14.23%
2005 66.132.000 19.97%
2006 73.351.000 9.84%
2007 85.111.000 13.82%
2008 103.558.000 17.81%
2009 105.242.000 1.6%
2010 109.776.000 4.13%
2011 112.302.000 2.25%
2012 112.331.000 0.03%
2013 112.561.000 0.2%
2014 110.948.000 -1.45%
2015 107.735.000 -2.98%
2016 104.476.000 -3.12%
2017 77.286.000 -35.18%
2018 125.350.000 38.34%
2019 96.072.000 -30.48%
2020 229.296.000 58.1%
2021 140.410.000 -63.3%
2022 272.051.000 48.39%
2023 285.263.000 4.63%
2024 203.972.000 -39.85%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bio-Techne Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 0%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 2 100%
2021 1 0%
2022 2 100%
2023 2 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bio-Techne Corporation Free Cashflow
Year Free Cashflow Growth
1990 700.000
1991 900.000 22.22%
1992 3.300.000 72.73%
1993 1.900.000 -73.68%
1994 5.000.000 62%
1995 6.000.000 16.67%
1996 3.400.000 -76.47%
1997 8.300.000 59.04%
1998 17.300.000 52.02%
1999 -2.200.000 886.36%
2000 8.371.541 126.28%
2001 39.556.758 78.84%
2002 5.390.965 -633.76%
2003 38.895.139 86.14%
2004 61.843.000 37.11%
2005 63.023.000 1.87%
2006 80.986.000 22.18%
2007 82.427.000 1.75%
2008 98.952.000 16.7%
2009 104.765.000 5.55%
2010 106.616.000 1.74%
2011 123.564.000 13.72%
2012 120.729.000 -2.35%
2013 101.108.000 -19.41%
2014 122.941.000 17.76%
2015 119.454.000 -2.92%
2016 126.972.000 5.92%
2017 128.269.000 1.01%
2018 149.433.000 14.16%
2019 156.208.000 4.34%
2020 153.473.000 -1.78%
2021 307.863.000 50.15%
2022 280.364.000 -9.81%
2023 216.149.000 -29.71%
2024 45.791.000 -372.03%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bio-Techne Corporation Operating Cashflow
Year Operating Cashflow Growth
1990 1.100.000
1991 1.800.000 38.89%
1992 3.900.000 53.85%
1993 4.500.000 13.33%
1994 6.300.000 28.57%
1995 7.300.000 13.7%
1996 9.800.000 25.51%
1997 12.500.000 21.6%
1998 20.300.000 38.42%
1999 28.400.000 28.52%
2000 38.739.403 26.69%
2001 46.371.711 16.46%
2002 27.667.227 -67.61%
2003 54.088.895 48.85%
2004 65.553.000 17.49%
2005 74.433.000 11.93%
2006 85.589.000 13.03%
2007 90.503.000 5.43%
2008 115.317.000 21.52%
2009 111.321.000 -3.59%
2010 111.260.000 -0.05%
2011 127.194.000 12.53%
2012 126.746.000 -0.35%
2013 123.562.000 -2.58%
2014 136.762.000 9.65%
2015 139.359.000 1.86%
2016 143.870.000 3.14%
2017 143.448.000 -0.29%
2018 170.367.000 15.8%
2019 181.619.000 6.2%
2020 205.217.000 11.5%
2021 352.164.000 41.73%
2022 325.272.000 -8.27%
2023 254.393.000 -27.86%
2024 59.383.000 -328.39%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bio-Techne Corporation Capital Expenditure
Year Capital Expenditure Growth
1990 400.000
1991 900.000 55.56%
1992 600.000 -50%
1993 2.600.000 76.92%
1994 1.300.000 -100%
1995 1.300.000 0%
1996 6.400.000 79.69%
1997 4.200.000 -52.38%
1998 3.000.000 -40%
1999 30.600.000 90.2%
2000 30.367.862 -0.76%
2001 6.814.953 -345.61%
2002 22.276.262 69.41%
2003 15.193.756 -46.61%
2004 3.710.000 -309.54%
2005 11.410.000 67.48%
2006 4.603.000 -147.88%
2007 8.076.000 43%
2008 16.365.000 50.65%
2009 6.556.000 -149.62%
2010 4.644.000 -41.17%
2011 3.630.000 -27.93%
2012 6.017.000 39.67%
2013 22.454.000 73.2%
2014 13.821.000 -62.46%
2015 19.905.000 30.57%
2016 16.898.000 -17.8%
2017 15.179.000 -11.32%
2018 20.934.000 27.49%
2019 25.411.000 17.62%
2020 51.744.000 50.89%
2021 44.301.000 -16.8%
2022 44.908.000 1.35%
2023 38.244.000 -17.42%
2024 13.592.000 -181.37%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bio-Techne Corporation Equity
Year Equity Growth
1989 3.100.000
1990 4.600.000 32.61%
1991 6.300.000 26.98%
1992 11.200.000 43.75%
1993 17.800.000 37.08%
1994 23.000.000 22.61%
1995 29.500.000 22.03%
1996 38.900.000 24.16%
1997 48.100.000 19.13%
1998 63.800.000 24.61%
1999 96.800.000 34.09%
2000 141.145.378 31.42%
2001 177.660.268 20.55%
2002 206.516.783 13.97%
2003 236.617.194 12.72%
2004 297.425.000 20.44%
2005 267.869.000 -11.03%
2006 340.348.000 21.3%
2007 437.651.000 22.23%
2008 487.130.000 10.16%
2009 456.482.000 -6.71%
2010 501.792.000 9.03%
2011 586.122.000 14.39%
2012 674.442.000 13.1%
2013 737.541.000 8.56%
2014 795.265.000 7.26%
2015 846.935.000 6.1%
2016 879.280.000 3.68%
2017 950.827.000 7.52%
2018 1.079.145.000 11.89%
2019 1.165.589.000 7.42%
2020 1.381.192.000 15.61%
2021 1.579.497.000 12.55%
2022 1.700.252.000 7.1%
2023 1.966.516.000 13.54%
2024 1.997.746.000 1.56%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bio-Techne Corporation Assets
Year Assets Growth
1989 6.100.000
1990 8.000.000 23.75%
1991 9.600.000 16.67%
1992 15.700.000 38.85%
1993 20.400.000 23.04%
1994 26.800.000 23.88%
1995 34.100.000 21.41%
1996 44.400.000 23.2%
1997 53.900.000 17.63%
1998 72.900.000 26.06%
1999 123.800.000 41.11%
2000 180.409.581 31.38%
2001 215.525.113 16.29%
2002 238.246.959 9.54%
2003 263.277.128 9.51%
2004 325.460.000 19.11%
2005 295.263.000 -10.23%
2006 370.512.000 20.31%
2007 454.844.000 18.54%
2008 507.369.000 10.35%
2009 472.005.000 -7.49%
2010 518.816.000 9.02%
2011 617.670.000 16%
2012 719.324.000 14.13%
2013 778.098.000 7.55%
2014 862.491.000 9.78%
2015 1.063.360.000 18.89%
2016 1.129.507.000 5.86%
2017 1.556.653.000 27.44%
2018 1.593.202.000 2.29%
2019 1.884.410.000 15.45%
2020 2.027.589.000 7.06%
2021 2.262.957.000 10.4%
2022 2.294.805.000 1.39%
2023 2.638.692.000 13.03%
2024 2.755.360.000 4.23%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bio-Techne Corporation Liabilities
Year Liabilities Growth
1989 3.000.000
1990 3.400.000 11.76%
1991 3.300.000 -3.03%
1992 4.500.000 26.67%
1993 2.600.000 -73.08%
1994 3.800.000 31.58%
1995 4.600.000 17.39%
1996 5.500.000 16.36%
1997 5.800.000 5.17%
1998 9.100.000 36.26%
1999 27.000.000 66.3%
2000 39.264.203 31.24%
2001 37.864.845 -3.7%
2002 31.730.176 -19.33%
2003 26.659.934 -19.02%
2004 28.035.000 4.9%
2005 27.394.000 -2.34%
2006 30.164.000 9.18%
2007 17.193.000 -75.44%
2008 20.239.000 15.05%
2009 15.523.000 -30.38%
2010 17.024.000 8.82%
2011 31.548.000 46.04%
2012 44.882.000 29.71%
2013 40.557.000 -10.66%
2014 67.226.000 39.67%
2015 216.425.000 68.94%
2016 250.227.000 13.51%
2017 605.826.000 58.7%
2018 514.057.000 -17.85%
2019 718.821.000 28.49%
2020 646.397.000 -11.2%
2021 691.723.000 6.55%
2022 593.794.000 -16.49%
2023 672.176.000 11.66%
2024 757.614.000 11.28%

Bio-Techne Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
7.23
Net Income per Share
1.56
Price to Earning Ratio
47.28x
Price To Sales Ratio
10.2x
POCF Ratio
45.26
PFCF Ratio
54.15
Price to Book Ratio
5.84
EV to Sales
10.55
EV Over EBITDA
29.6
EV to Operating CashFlow
46.82
EV to FreeCashFlow
56.01
Earnings Yield
0.02
FreeCashFlow Yield
0.02
Market Cap
11,66 Bil.
Enterprise Value
12,07 Bil.
Graham Number
21.06
Graham NetNet
-2.29

Income Statement Metrics

Net Income per Share
1.56
Income Quality
1.04
ROE
0.13
Return On Assets
0.08
Return On Capital Employed
0.1
Net Income per EBT
0.89
EBT Per Ebit
0.94
Ebit per Revenue
0.23
Effective Tax Rate
0.11

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.67
Operating Profit Margin
0.23
Pretax Profit Margin
0.22
Net Profit Margin
0.2

Dividends

Dividend Yield
0
Dividend Yield %
0.43
Payout Ratio
0.2
Dividend Per Share
0.32

Operating Metrics

Operating Cashflow per Share
1.63
Free CashFlow per Share
1.36
Capex to Operating CashFlow
-0.16
Capex to Revenue
-0.04
Capex to Depreciation
-0.39
Return on Invested Capital
0.1
Return on Tangible Assets
0.2
Days Sales Outstanding
65.27
Days Payables Outstanding
78.15
Days of Inventory on Hand
184.28
Receivables Turnover
5.59
Payables Turnover
4.67
Inventory Turnover
1.98
Capex per Share
-0.27

Balance Sheet

Cash per Share
0,94
Book Value per Share
12,63
Tangible Book Value per Share
2.84
Shareholders Equity per Share
12.63
Interest Debt per Share
3.51
Debt to Equity
0.28
Debt to Assets
0.2
Net Debt to EBITDA
0.98
Current Ratio
4.63
Tangible Asset Value
0,45 Bil.
Net Current Asset Value
-0,17 Bil.
Invested Capital
0.28
Working Capital
0,46 Bil.
Intangibles to Total Assets
0.56
Average Receivables
0,21 Bil.
Average Payables
0,08 Bil.
Average Inventory
178859000
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bio-Techne Corporation Dividends
Year Dividends Growth
2008 0
2009 1 100%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 0 0%

Bio-Techne Corporation Profile

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

CEO
Mr. Kim Kelderman
Employee
3.200
Address
614 McKinley Place N.E.
Minneapolis, 55413

Bio-Techne Corporation Executives & BODs

Bio-Techne Corporation Executives & BODs
# Name Age
1 Mr. James T. Hippel
Executive Vice President of Finance & Chief Financial Officer
70
2 Mr. Charles R. Kummeth
Senior Advisor
70
3 Mr. William A. Geist
President of Protein Sciences Segment
70
4 Ms. Brenda S. Everson
Senior Vice President & Chief Human Resources Officer
70
5 David Clair
Senior Director of Investor Relations & Corporate Development
70
6 Mr. Kim Kelderman
Chief Executive Officer, President & Director
70
7 Mr. Gerry Andros
Vice President of Sales and Marketing
70
8 Dr. Gary J. Latham Ph.D.
Vice President & Chief Technology Officer
70
9 Mr. Robert M. Gavin
Vice President of Corporate Development
70
10 Mr. Shane Bohnen
Senior Vice President, General Counsel & Corporate Secretary
70

Bio-Techne Corporation Competitors